Drug intelligence / Profile preview

P-AML-2025

Development stage: Preclinical
Lead developer: Institute of Hematology and Blood Diseases Hospital
Modality: Small Molecules

Overview

**P-AML-2025** is an investigator-initiated, named treatment regimen/protocol for children with newly diagnosed acute myeloid leukemia, excluding acute promyelocytic leukemia and several secondary or genetically defined AML subgroups. It is being evaluated by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College in the prospective ChiCTR study ChiCTR2500096333. The public registry identifies the regimen but does not disclose its individual active pharmaceutical components, doses, or target-specific mechanism. Study endpoints include complete remission, measurable residual disease negativity, event-free survival, overall survival, safety, and exploratory RNA-sequencing correlates of response and resistance.

Other names: P-AML-2025 regimenP-AML2025 regimenP-AML 2025 regimen

Targets

TOP2A (DNA topoisomerase II)DNA at Topoisomerase II cleavage sites

Beyond the preview

Go deeper on P-AML-2025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-AML-2025.

Explore the full profile